Form 8-K · Current Report · Filed 2025-08-01
Moderna Reports Second Quarter 2025 Financial Results and Business Updates
Moderna, Inc. reported its financial results for the second quarter of 2025, showing a total revenue of $142 million, a GAAP net loss of $(0.8) billion, and GAAP EPS of $(2.13). The company updated its 2025 projected revenue range to $1.5 to $2.2 billion, primarily due to the timing of contracted revenue deliveries. Moderna also reduced its expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion. The company reiterated its 2025 expected year-end cash balance of approximately $6 billion. Moderna announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for its seasonal influenza vaccine.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001682852-25-000041
- CIK
- 0001682852
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$29.56
Next session
-6.5%
Since filing
+85.5%
Latest close
$54.82
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Exhibits (1)
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.